gemcitabine + pirarubicin

Gemcitabine + pirarubicin is an experimental combination chemotherapy regimen consisting of two small molecule chemotherapeutic agents, gemcitabine and pirarubicin. Gemcitabine is a nucleoside analog antimetabolite that inhibits DNA synthesis by incorporation into DNA and inhibition of ribonucleotide reductase, leading to cell cycle arrest and apoptosis. Pirarubicin is an anthracycline antibiotic structurally related to doxorubicin; it intercalates into DNA, inhibits topoisomerase II, and generates free radicals, resulting in cytotoxicity primarily through DNA damage. The combination has been investigated for synergistic anti-tumor activity in preclinical models (notably breast cancer) using advanced delivery systems such as pH-responsive polymeric nanoparticles for targeted release within the tumor microenvironment[2][3]. This dual-drug approach aims to maximize efficacy while minimizing toxicity by leveraging complementary mechanisms of action.

Other names

pirarubicin and gemcitabine combinationPira-Gem